newsfilter
← Latest News
Business Wire·

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results

Announced global epigenetic regulation and capsid delivery license agreement with Genentech to develop novel genomic medicines for neurodegenerative diseases. Expect to receive $50 million in near-term upfront license